March 04, 2021 11:00 ET | Source: Berlin Heals Holding AG
BERLIN and ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- BERLIN HEALS, a company dedicated to developing and offering novel and life-saving treatments for patients suffering from heart failure, announces results of a first-in-human study published in ESC Heart Failure, in patients with dilated cardiomyopathy for its proprietary C-MIC device. The C-MIC is a small implantable device that delivers a minimal constant electrical DC current to the heart. The results show significant, rapid improvements in heart function, heart size and quality of life of patients. Thus, this treatment has the potential to become the first sustainable, almost curative, treatment for heart failure in patients with unmet medical needs.
Results from the first-in-human study involving 10 patients show that the C-MIC device significantly improved cardiac performance by two levels of the New York Heart Association (NYHA) classification and quality of life of patients with NYHA class III heart failure. Heart failure is the world's most lethal disease, accounting for 16% of all deaths globally. As of today, no therapy, drug or method has been developed and made available to treat cardiac failure for a patient to be enabled a normal and mobile life. The last hope for most of these seriously ill patients are Ventricular Assist Devices (VAD) which are very often associated with significant side effects and a statistically short life expectancy. They serve at most as a "bridge to transplant," that is, if a transplant becomes available at all.
Since 2014, the Berlin Heals team has been developing a new and revolutionary technology to treat heart failure. After confirmation from preclinical trials that microcurrents have a regenerative and anti-inflammatory effect on heart cells, the company developed and widely tested its proprietary C-MIC device which restores endogenous electric potential gradients using microcurrents, leading to improved myocardial function. The C-MIC is a small implantable device that delivers a constant electrical DC current equivalent to physiological strength to the heart via two leads, one placed on the epicardium of the left ventricle, and the other in the right ventricular cavity. Extensive preclinical trials confirmed that microcurrent application via C-MIC promotes reverse remodeling of heart muscle tissue and a strong anti-inflammatory effect in a safe and effective manner. Following this work, Berlin Heals moved on to test their technology in patients.
The results of the first-in-human study of 10 patients are extremely positive, demonstrating rapid and lasting improvement in heart function within days of C-MIC placement. Patients mean 6-minute walking distance improved by almost 100% in 14 days and all of the patients' hearts, which were typically enlarged in dilated cardiomyopathies, had shrunk. All patients saw NYHA classification drop by two classes. The electrical microcurrent remained completely undetectable to the patients and did not interfere with the heart rhythm. No device-specific side-medication or follow-up procedures were required. The patients maintained and increased these improvements for 6 months after implantation and at least another 6 months post deactivation of C-MIC.
"We were very pleased to see that our patients, who previously could barely walk 200 meters during the 6-minute walk test, were now able to walk more than 400 meters only two weeks after the C-MIC device had been implanted - almost reaching the level of healthy patients," says Marko Bagaric, CEO of Berlin Heals. "We continue to see stable parameters after now more than 12 months and above all, happy and mobile patients. Our new method has a realistic potential to almost cure heart failure, rather than just delaying the progression of the disease."
"It is of utmost importance to note that our C-MIC device can be implanted with pacemakers or VAD pumps and will work independently or in parallel to such implants without any cross-interferences," explains Dr. Johannes Mller, Scientific Director and Chairman of the Board of Directors of Berlin Heals. "Even in the case of seriously ill patients with already very low pumping capacity, a VAD together with our C-MIC device can be implanted and remain until the patient's heart recovers. We are talking about a real paradigm shift in the treatment of heart failure, which millions of patients will benefit from. And in combination with VADs, the microcurrent method will be a 'bridge to the regeneration' of the heart, rather than a 'bridge to transplantation'."
Berlin Heals has now launched a CE mark study with its C-MIC device to confirm the successful results obtained in the first-in-human study within a larger group of patients, and preliminary data is confirming data from the pilot study.
About BERLIN HEALS
Berlin Heals Holding AG, a Swiss company operating an R&D subsidiary in Berlin, Germany, was founded in 2014 as an innovative life science company with the mission to develop its proprietary C-MIC technology to treat heart failure. The C-MIC device is a novel cardiac implant using constant microcurrent to treat heart failure and meanwhile has turned out to represent a breakthrough near-curative treatment for patients with systematic and refractory heart failure. After the completion of the CE-study, the company intends to test the efficacy of its technology also with patients suffering from heart failure with preserved ejection fractions (HFpEF-patients).
About Heart Failure
In the US alone, 1 in every 4 deaths are due to heart disease, resulting in attributable disease costs of about $220 billion annually. It has shown the largest increase amongst all fatal diseases since 2000, rising by more than 2 million to 8.9 million deaths in 2019.
Full publication DOI: 10.1002/ehf2.13242
SOURCE BERLIN HEALS
The rest is here:
BERLIN HEALS Announces results of first-in-human study for its Implantable C-MIC device for the Treatment of Heart Failure with Electrical...
- Cardiac MR PET CT Program - Massachusetts General Hospital, Boston, MA - April 12th, 2018 [April 12th, 2018]
- The History, Physical Examination, and Cardiac ... - April 21st, 2018 [April 21st, 2018]
- Dor procedure - Wikipedia - April 26th, 2018 [April 26th, 2018]
- Cardiac Remodeling and Its Significance - Verywell - May 13th, 2018 [May 13th, 2018]
- AndrewMcCulloch - Cardiac Mechanics Research Group - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardiac Nursing Events ... - June 3rd, 2018 [June 3rd, 2018]
- Cardiac MR PET CT Program - Massachusetts General Hospital ... - June 5th, 2018 [June 5th, 2018]
- Cardiac resynchronization therapy - Wikipedia - June 23rd, 2018 [June 23rd, 2018]
- Cardiac Remodeling and Its Significance - verywellhealth.com - October 5th, 2018 [October 5th, 2018]
- Ventricular remodeling - Wikipedia - December 21st, 2018 [December 21st, 2018]
- The Significance of Cardiac Remodeling - verywellhealth.com - December 21st, 2018 [December 21st, 2018]
- Ventricular hypertrophy - Wikipedia - December 26th, 2018 [December 26th, 2018]
- Cardiac remodelingconcepts and clinical implications: a ... - April 3rd, 2019 [April 3rd, 2019]
- Emerging roles of proteoglycans in cardiac remodeling ... - May 23rd, 2019 [May 23rd, 2019]
- Antibody could fine-tune recovery from heart attack - Futurity: Research News - September 27th, 2019 [September 27th, 2019]
- What are the respiratory effects of e-cigarettes? - The BMJ - October 3rd, 2019 [October 3rd, 2019]
- AI Pinpoints Genes Associated With Heart Failure - Forbes - October 3rd, 2019 [October 3rd, 2019]
- PH Common in Myeloproliferative Neoplasms, Linked to Diastolic Dysfunction - The Cardiology Advisor - October 26th, 2019 [October 26th, 2019]
- Effects of genetic transfection on calcium cycling pathways mediated by double-stranded adeno-associated virus in postinfarction remodeling - DocWire... - November 6th, 2019 [November 6th, 2019]
- Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019 - GlobeNewswire - November 15th, 2019 [November 15th, 2019]
- Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights - P&T Community - November 15th, 2019 [November 15th, 2019]
- Ibrutinib and Hypertension in CLL: What Are the Risks? - Cancer Therapy Advisor - November 23rd, 2019 [November 23rd, 2019]
- What's being done to close the research gap when it comes to men's and women's cardiac health - The Loop - November 23rd, 2019 [November 23rd, 2019]
- Heart Ventricle Remodeling - an overview | ScienceDirect ... - November 26th, 2019 [November 26th, 2019]
- Denise Merkl, 1949-2019 The Times-Independent - The Times-Independent - December 16th, 2019 [December 16th, 2019]
- Is There a Future for CAR T-Cell Therapy in Heart Failure? - AJMC.com Managed Markets Network - December 16th, 2019 [December 16th, 2019]
- $13 Million Grant to Probe the Genome of Heart Cells - PRNewswire - December 18th, 2019 [December 18th, 2019]
- TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure - BioSpace - December 18th, 2019 [December 18th, 2019]
- News - Michigan Lawmaker to Offer CON Reforms - The Heartland Institute - December 28th, 2019 [December 28th, 2019]
- Personalized Medicine for AFib: How Electric Activity in the Heart Can Predict Individual Progression of Atrial Fibrillation - DocWire News - December 28th, 2019 [December 28th, 2019]
- Cardiac Restoration Systems Market Drives, Emerging Trends, Key Value And Forecast 2025 - Industry Mirror - December 31st, 2019 [December 31st, 2019]
- New Living Machines Are Created in the Lab - Tufts Now - January 16th, 2020 [January 16th, 2020]
- Man thinks sepsis was a cold and loses his leg on his 40th birthday - Information-Analytic Agency NEWS.am - January 25th, 2020 [January 25th, 2020]
- Could Colchicine Be the New Aspirin? - Medscape - January 28th, 2020 [January 28th, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - Renal and Urology News - January 28th, 2020 [January 28th, 2020]
- Link between chronic kidney disease and heart failure is identified in patients - UAB News - February 9th, 2020 [February 9th, 2020]
- Advancing an oral drug for pulmonary arterial hypertension - Penn: Office of University Communications - February 15th, 2020 [February 15th, 2020]
- MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR - TCTMD - February 15th, 2020 [February 15th, 2020]
- Varied Nightly Bedtime, Sleep Duration Linked to CVD Risk - Medscape - March 4th, 2020 [March 4th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Business Wire - March 4th, 2020 [March 4th, 2020]
- Slump in Production of Absorbable Heart Stent Amidst Covid-19 Outbreak to Diminish Prospects of Sales - Jewish Life News - May 7th, 2020 [May 7th, 2020]
- Cardiol Therapeutics files patent to use CBD therapies for patients with coronavirus - Proactive Investors USA & Canada - May 7th, 2020 [May 7th, 2020]
- The Effector Cells and Cellular Mediators of Immune System Involved in Cardiac Inflammation and Fibrosis after Myocardial Infarction - DocWire News - May 7th, 2020 [May 7th, 2020]
- Cardiac Restoration Systems Market Detailed Analysis and Forecast 2018-2028 3w Market News Reports - 3rd Watch News - May 16th, 2020 [May 16th, 2020]
- LV Mass Regression After TAVR Linked to Better Long-term Outcomes - TCTMD - May 16th, 2020 [May 16th, 2020]
- Hypoxic Training Equipment Industry to 2026; Featuring Profiles of Biomedtech Australia, Go2 Altitude, Gooxygen, Higher Peak, and More - GlobeNewswire - May 16th, 2020 [May 16th, 2020]
- Surplus antioxidants are pathogenic for hearts and skeletal muscle - The Mix - May 16th, 2020 [May 16th, 2020]
- $125619 awarded in spring Community Needs Grants - The MidWeek - May 20th, 2020 [May 20th, 2020]
- Absorbable Cardiac Stent Market 2020-2026 Growth Trends, Leading Players, Competitive Strategies and 2026 Future Prospect - Cole of Duty - June 15th, 2020 [June 15th, 2020]
- The Protective Effects of Liguzinediol on Congestive Heart Failure Induced by Myocardial Infarction and Its Relative Mechanism - DocWire News - June 19th, 2020 [June 19th, 2020]
- ABSORBABLE HEART STENT Sales Market 2020-2026: Analysis by Growth Factors, Key Trends and Competitive Strategies - Cole of Duty - June 19th, 2020 [June 19th, 2020]
- Absorbable Heart Stent Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:... - June 19th, 2020 [June 19th, 2020]
- Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease - Science Advances - June 19th, 2020 [June 19th, 2020]
- Worldwide Comprehensive Review of Absorbable Cardiac Stent Market Trends and Its Development - 3rd Watch News - June 22nd, 2020 [June 22nd, 2020]
- Absorbable Heart Stent Market In-deep Analysis And Experts Review Report 2020-2026 - Cole of Duty - June 22nd, 2020 [June 22nd, 2020]
- Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No... - July 1st, 2020 [July 1st, 2020]
- Cardiac Restoration Systems Market Analysis with Key Players, Applications, Trends and Forecast to 2027 - Jewish Life News - July 1st, 2020 [July 1st, 2020]
- Women Thrive on Baroreflex Activation for Heart Failure - Medscape - July 1st, 2020 [July 1st, 2020]
- Meet Inspiring young Doctor from Gallipolis, Ohio USA: Dr Wilton Triggs II - International Business Times, Singapore Edition - August 19th, 2020 [August 19th, 2020]
- Absorbable Heart Stent Market Research 2020-Competitive Insights: Abbott Laboratories, Biotronik, Arterial Remodeling Technologies, Amaranth Medica -... - August 19th, 2020 [August 19th, 2020]
- Novel mechanism connects SPEG, RyR2 and atrial fibrillation - Baylor College of Medicine News - August 19th, 2020 [August 19th, 2020]
- Comprehensive Analysis On Absorbable Heart Stent Market Insights Abbott Laboratories, Biotronik, Arterial Remodeling Technologies, Amaranth Medica -... - August 28th, 2020 [August 28th, 2020]
- Lincolnton man wrestles with COVID and wins | News - Lincoln Times-News - August 28th, 2020 [August 28th, 2020]
- Impact of sex on timing and clinical outcome of septal myectomy for obstructive hypertrophic cardiomyopathy - DocWire News - August 28th, 2020 [August 28th, 2020]
- Adverse Remodeling in Atrial Fibrillation Following Isolated Aortic Valve Replacement Surgery - DocWire News - August 28th, 2020 [August 28th, 2020]
- EphrinA1-Fc Attenuates Ventricular Remodeling and Dysfunction in Chronically Nonreperfused WT but not EphA2-R-M mice - DocWire News - August 28th, 2020 [August 28th, 2020]
- Business Notebook: Several 'pro-business' laws now in effect; SEMO joins forces with Codefi - Southeast Missourian - August 31st, 2020 [August 31st, 2020]
- Global Absorbable Heart Stent Market Covid-19 Impact Analysis, Leading Player, Application, New Product Developments and 2024 Forecast - The Daily... - August 31st, 2020 [August 31st, 2020]
- Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week - DocWire News - August 31st, 2020 [August 31st, 2020]
- Microengineered 3D pulmonary interstitial mimetics highlight a critical role for matrix degradation in myofibroblast differentiation - Science... - September 15th, 2020 [September 15th, 2020]
- 3D curvature-instructed endothelial flow response and tissue vascularization - Science Advances - September 19th, 2020 [September 19th, 2020]
- FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity - Science Advances - September 19th, 2020 [September 19th, 2020]
- Denervation Therapy Ventures Where Drugs Have Failed: HFpEF - Medscape - October 14th, 2020 [October 14th, 2020]
- Comprehensive Report on Absorbable Heart Stent Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Impact Of Covid 19 Analysis... - November 26th, 2020 [November 26th, 2020]
- Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study... - November 26th, 2020 [November 26th, 2020]
- NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 -... - December 17th, 2020 [December 17th, 2020]
- Elite Soccer Players Have Big Hearts and That's Okay - Medscape - December 20th, 2020 [December 20th, 2020]
- A high triglyceride-glucose index is associated with left ventricular dysfunction and atherosclerosis - DocWire News - January 20th, 2021 [January 20th, 2021]
- Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System - Business Wire - January 20th, 2021 [January 20th, 2021]
- Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis - DocWire... - January 20th, 2021 [January 20th, 2021]